🇺🇸 FDA
Patent

US 8415384

Reducing myocardial reperfusion injury by the combination therapy of protein kinase A activation and B1-adrenergic receptor blockade

granted A61KA61K31/24A61K31/444

Quick answer

US patent 8415384 (Reducing myocardial reperfusion injury by the combination therapy of protein kinase A activation and B1-adrenergic receptor blockade) held by The Board of Regents of the University of Texas System expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/24, A61K31/444, A61K45/06, A61P